The use of G-CSF in CRT is still controversial and most recent recommendations on its use derive from studies in chest malignancies.[24,25] Even if neutropenia is reversed, old reports for abdominal RT and extended field CRT in chest malignancies stated a small number patients had severe thrombocytopenia with the use of G-CSF.[26] This led ASCO to recommend against use of CSFs for CRT, but these recommendations are being questioned.[24,27]. The gene discussed is CSF3; the disease is Decreased total neutrophil count.